Going forward, gastric and colorectal adenocarcinomas may be the indications in which [89Zr]Zr-DFO-D2101 will have the most utility, as patients with each have been shown to express CDH17, and both cancers are plagued by a lack of reliable radiotheranostics [27]. The gene discussed is CDH17; the disease is cancer.